BR112019005167A2 - método e kit para analisar uma amostra - Google Patents

método e kit para analisar uma amostra

Info

Publication number
BR112019005167A2
BR112019005167A2 BR112019005167A BR112019005167A BR112019005167A2 BR 112019005167 A2 BR112019005167 A2 BR 112019005167A2 BR 112019005167 A BR112019005167 A BR 112019005167A BR 112019005167 A BR112019005167 A BR 112019005167A BR 112019005167 A2 BR112019005167 A2 BR 112019005167A2
Authority
BR
Brazil
Prior art keywords
analyzing
kit
sample
suspected
kits
Prior art date
Application number
BR112019005167A
Other languages
English (en)
Inventor
j sexton Daniel
Viswanathan Malini
FAUCETTE Ryan
Gaur Tripti
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of BR112019005167A2 publication Critical patent/BR112019005167A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Abstract

proveem-se, neste documento, métodos e kits para analisar uma amostra biológica obtida a partir de um indivíduo tendo, com suspeita de ter ou com risco de ter uma doença associada ao sistema de ativação por contato.
BR112019005167A 2016-09-16 2017-09-15 método e kit para analisar uma amostra BR112019005167A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US201762518367P 2017-06-12 2017-06-12
PCT/US2017/051755 WO2018053247A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Publications (1)

Publication Number Publication Date
BR112019005167A2 true BR112019005167A2 (pt) 2019-07-02

Family

ID=59974882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005167A BR112019005167A2 (pt) 2016-09-16 2017-09-15 método e kit para analisar uma amostra

Country Status (13)

Country Link
US (2) US11340237B2 (pt)
EP (1) EP3513197A1 (pt)
JP (3) JP7225090B2 (pt)
KR (2) KR102464380B1 (pt)
CN (2) CN117169508A (pt)
AU (2) AU2017325986B2 (pt)
BR (1) BR112019005167A2 (pt)
CA (1) CA3037157A1 (pt)
CO (1) CO2019002607A2 (pt)
IL (1) IL265199A (pt)
MX (1) MX2019002918A (pt)
NZ (1) NZ751481A (pt)
WO (1) WO2018053247A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3096798T3 (pl) * 2014-01-21 2021-07-26 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego
CN109716138B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
ES2372978T3 (es) 2002-06-07 2012-01-30 Dyax Corp. Polipéptido con dominio de kunitz modificado.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1711828A2 (en) 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1949105A4 (en) 2005-10-11 2009-06-17 Tethys Bioscience Inc MARKERS ASSOCIATED WITH DIABETES AND METHODS OF USE THEREOF
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
WO2008016883A2 (en) * 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008019052A2 (en) 2006-08-03 2008-02-14 Numira Biosciences, Inc. Methods and compositions for identifying biomarkers
EP2118135A1 (en) 2006-10-16 2009-11-18 Bayer Schering Pharma AG Crtac as a biomarker, therapeutic and diagnostic target
EP2087359A1 (en) 2006-10-16 2009-08-12 Bayer Schering Pharma AG Prss23 as a biomarker, therapeutic and diagnostic target
US20110111394A1 (en) 2006-10-16 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Ctgf as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
FR2914066B1 (fr) * 2007-03-20 2009-05-22 Polyintell Sarl Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant
CN105675892A (zh) 2008-04-29 2016-06-15 赛凯米迪克斯股份有限公司 固相多分析物测试
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK2466312T3 (da) * 2009-08-12 2020-01-13 Human Metabolome Tech Inc Phosphoethanolamine som biomarkør for depression
WO2011051805A1 (en) 2009-10-27 2011-05-05 Anaxomics Biotech Sl Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
RU2012122180A (ru) * 2009-10-30 2013-12-10 Нестек С.А. Способы диагностики синдрома раздраженного кишечника
ES2532006T3 (es) 2009-11-20 2015-03-23 Pharnext Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth
PT2521568T (pt) 2010-01-06 2018-10-26 Dyax Corp Proteínas de ligação à calicreína plasmática
MX2012010852A (es) 2010-03-23 2013-04-03 Purdue Research Foundation Deteccion temprana de cancer de mama recurrente, que utiliza el perfilado de metabolismo.
KR102169651B1 (ko) 2011-01-06 2020-10-23 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
JP6679309B2 (ja) * 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
US20140086825A1 (en) 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
DK2946206T3 (en) 2013-01-20 2019-04-15 Dyax Corp EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS
BR112015022846A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
DK2970106T3 (en) * 2013-03-15 2018-08-13 Intrexon Corp CONTAINING DIACYL HYDRAZINES
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
AU2015321470B2 (en) 2014-09-22 2018-11-15 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
BR112017020864A2 (pt) * 2015-03-30 2018-07-10 Dyax Corp inibidores de calicreína plasmática e usos dos mesmos para a prevenção de ataque de angioedema hereditário
EA201890478A1 (ru) 2015-08-13 2018-07-31 Дайэкс Корп. Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
EP3513188A1 (en) 2016-09-16 2019-07-24 Dyax Corp. Rna biomarkers for hereditary angioedema
CN109716138B (zh) 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记

Also Published As

Publication number Publication date
US20190361036A1 (en) 2019-11-28
US20220365101A1 (en) 2022-11-17
NZ751481A (en) 2024-02-23
AU2017325986B2 (en) 2023-12-14
CA3037157A1 (en) 2018-03-22
CO2019002607A2 (es) 2019-03-29
KR102464380B1 (ko) 2022-11-07
MX2019002918A (es) 2019-07-18
CN109716137B (zh) 2023-07-21
AU2017325986A1 (en) 2019-04-04
JP2023058612A (ja) 2023-04-25
EP3513197A1 (en) 2019-07-24
JP7451791B2 (ja) 2024-03-18
WO2018053247A1 (en) 2018-03-22
US11340237B2 (en) 2022-05-24
JP2019534446A (ja) 2019-11-28
AU2024200561A1 (en) 2024-02-15
IL265199A (en) 2019-05-30
JP7225090B2 (ja) 2023-02-20
KR20190053914A (ko) 2019-05-20
JP2024059990A (ja) 2024-05-01
KR20220154245A (ko) 2022-11-21
CN117169508A (zh) 2023-12-05
CN109716137A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
BR112019005172A2 (pt) método e kit para analisar uma amostra
BR112019005167A2 (pt) método e kit para analisar uma amostra
WO2020123316A3 (en) Methods for determining a location of a biological analyte in a biological sample
GB2556004A (en) Markers of stroke and stroke severity
BR112014031365A2 (pt) métodos de detectar doenças ou condições
PL413090A1 (pl) Startery, sposób mikrobiologicznej analizy materiału biologicznego, zastosowanie metody sekwencjonowania NGS w diagnostyce mikrobiologicznej i zestaw diagnostyczny
WO2015157407A8 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
MX2019003927A (es) Sistema de analisis y metodo para analizar una muestra.
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
JP2021503610A5 (pt)
BR112014026440A8 (pt) análises, métodos e aparelhos para avaliação de disrupção de rna.
IL263024A (en) Blood sample analysis method and system, for determining diabetes
BR112018015155A2 (pt) métodos para determinação da presença ou ausência de um micro-organismo em uma amostra, para testar rapidamente uma matriz alimentar e um micro-organismo alvo, e, composição.
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
WO2016198833A3 (en) Methods for analysing a urine sample
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
BR112019005179A2 (pt) método e kit para analisar uma amostra
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo
MX2020012713A (es) Metodos, dispositivos y sistemas para cuantificar biomarcadores.
BR112018000560A2 (pt) método para rastrear a disseminação da infecção, e sistema para rastrear a disseminação da infecção
WO2015038987A3 (en) System and method for whole-animal high-throughput compound screening
WO2018119437A3 (en) Electrophoresis diagnostic methods and kits

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]